Perimeter Medical 的 Claire 获 TIME 2026 年度最佳发明特别提名及多项行业奖项

Recognition from medtech, innovation, and business programs follows Claire's FDA approval and first U.S. commercial deployment at Intermountain Health

• Claire is the first FDA-approved, AI-enabled imaging device in the U.S. for intraoperative breast cancer margin assessment, helping surgeons evaluate removed tissue for suspicious areas while the patient is still in surgery.
• Claire earned a TIME Best Inventions special mention, a TAG Award, and Gold and Best of Category honors in the Globee Awards for Innovation.
• Additional finalist selections from Fierce Life Sciences and D CEO follow Claire's FDA approval and first U.S. commercial deployment at Intermountain Health.

TORONTO and DALLAS, /PRNewswire/ -- Perimeter Medical Imaging AI, Inc. ("Perimeter" or the "Company") (TSXV: PINK) (OTCQX: PYNKF), a commercial-stage medical technology company, today announced that Claire™, its AI-enabled imaging device for margin assessment during breast-conserving surgery, has received a special mention in TIME's Best Inventions of 2026, earning national recognition for its approach to helping surgeons identify difficult-to-see, potentially cancerous tissue during surgery. Additional industry recognitions include a TAG Award, Gold and Best of Category honors in the Globee® Awards for Innovation, and finalist selections in the 2026 Fierce Life Sciences Innovation Awards and D CEO's 2027 Innovation Awards.

During breast-conserving surgery, cancer cells at the edges of the removed tissue can be microscopic and difficult to detect during the initial procedure.¹ Patients typically must wait until after surgery for a final pathology report to confirm whether those margins are clear of cancer. If cancer is found at the tissue edges, patients may need another operation to remove additional tissue. Approximately one in five breast-conserving surgery patients require another operation because cancer is found at or near the edges of the removed tissue.²

Claire™, the first FDA-approved, AI-enabled imaging device in the U.S. for intraoperative breast cancer margin assessment, combines Perimeter's patented wide-field optical coherence tomography imaging with proprietary AI to provide three-dimensional, real-time visualization of excised tissue. Its AI identifies and marks focal areas suspicious for breast cancer, giving surgeons additional information to consider alongside other standard methods of margin assessment while the patient is still in the operating room.

"These honors recognize the work our team and clinical partners have put into bringing real-time, AI-enabled imaging into breast cancer surgery, with the goal of reducing the need for repeat operations and giving patients the best chance at recovery," said Perimeter CEO Adrian Mendes. "Cancer can be difficult to see during an operation, and finding it at the tissue margins afterward can mean another surgery for the patient. Our focus is on bringing Claire to more hospitals, so surgeons have additional information to guide critical decisions in real time during the initial procedure."

Recent recognitions announced for Perimeter and Claire include:

• TIME Best Inventions of 2026, Special Mention. Claire was named among a select group of special mentions on TIME's annual Best Inventions list, which recognizes products, software and services that TIME editors evaluate on originality, efficacy, ambition and impact. Claire was included on the Healthcare and Medical list for life-saving innovations in medical treatment and patient care.
• Fierce Life Sciences Innovation Awards, Finalist. Claire was named a finalist in the Medical Device Innovation category of the 2026 Fierce Life Sciences Innovation Awards. Presented by the publishers of Fierce Biotech and Fierce Pharma, the program highlights innovation that is driving improvement across the life sciences industry, and the Medical Device Innovation category honors devices advancing diagnostics, therapy delivery, or real-time monitoring.
• TAG Award for Medical Devices, Real-Time Surgical Intelligence. Perimeter won the TAG Award in the Real-Time Surgical Intelligence category for advancing intraoperative decision-making in cancer surgery. The TAG Awards for MedTech, Life Sciences, and BioTech recognize companies whose solutions show strong design, real-world relevance, market value, and the ability to improve outcomes across health care.
• Globee® Awards for Innovation (Golden Bridge Awards®), Gold and Best of Category. Perimeter received a Gold Globee Award and Best of Category honors in the Achievement in HealthTech Innovation category. The program recognizes achievements in innovation, product and service advancement, artificial intelligence and technology implementation across industries worldwide.
• D CEO 2027 Innovation Awards, Finalist. Perimeter was named a finalist in the Innovation in Healthcare and Biotech category of D CEO's 2027 Innovation Awards, which honor companies and leaders shaping North Texas as a hub for innovation. Winners will be announced in January 2027.

The recognition follows a milestone year for Claire. In 2026, Claire received U.S. Food and Drug Administration ("FDA") premarket approval and moved into clinical practice, with Intermountain Health becoming the first health system in the U.S. to commercially deploy the device.

To learn more about Perimeter Medical, please visit: www.perimetermed.com

Sources

¹ Levy Y, Rempel D, Nguyen M, Yassine A, Sanati-Burns M, Salgia P, Lim B, Butler SL, Berkeley A, Bayram E. The Fusion of Wide Field Optical Coherence Tomography and AI: Advancing Breast Cancer Surgical Margin Visualization. Life. 2023; 13(12):2340. https://doi.org/10.3390/life13122340.

² Kim Y, Ganduglia-Cazaban C, Tamirisa N, et al. Contemporary analysis of reexcision and conversion to mastectomy rates and associated healthcare costs for women undergoing breast-conserving surgery. Ann Surg Oncol. 2024;31(1):318-327.

About Perimeter Medical Imaging AI, Inc.

Based in Toronto, Canada and Dallas, Texas, Perimeter Medical Imaging AI (TSX-V: PINK) (OTCQX: PYNKF) is a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address areas of high unmet medical need. Claire™, recently approved by the FDA, is our next-generation AI-enabled device. The Company's ticker symbol "PINK" is a reference to the pink ribbons used during Breast Cancer Awareness Month.

Claire Indications for Use: The Claire OCT System is an adjunctive three-dimensional imaging tool, providing volumetric cross-sectional, real-time depth visualization, coupled with an artificial intelligence computer-aided detection algorithm, which identifies and marks focal areas suspicious for breast cancer. It is used concurrently with a physician's interpretation of the images. The Claire OCT System is intended for use in conjunction with other standard methods for evaluation of the margins of excised lumpectomy tissue during surgical procedures in patients with a biopsy-confirmed diagnosis of breast cancer.

The Claire OCT System should not be used to replace standard tissue histopathology assessment and should not be used for diagnosis. The device is not intended for use in any of the following individuals: under the age of 18, male, have metastatic cancer (Stage IV), have lobular carcinoma as their primary diagnosis, have had previous ipsilateral breast surgery for benign or malignant disease within two years (including implants and breast augmentation), patients with multi-centric disease (histologically diagnosed cancer in two different quadrants of the breast), unless resected in a single specimen, patients with bilateral disease (diagnosed cancer in both breasts), patients who are currently lactating, patients who are currently pregnant, or concurrent use in surgeries with cryo-assisted localization. Refer to prescriber labeling for full safety information.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This news release contains statements that constitute "forward-looking information" within the meaning of applicable Canadian securities legislation. In this news release, words such as "may," "would," "could," "will," "likely," "believe," "expect," "anticipate," "intend," "plan," "estimate," and similar words and the negative form thereof are used to identify forward-looking statements. Forward-looking information may relate to management's future outlook and anticipated events or results and may include statements or information regarding the future financial position, business strategy and strategic goals, competitive conditions, research and development activities, projected costs and capital expenditures, research and clinical testing outcomes, taxes and plans and objectives of, or involving, Perimeter. Without limitation, information regarding the potential benefits and the commercialization of Claire, including the potential market size for the device and building the next layer of Claire's AI infrastructure, are forward-looking information. Forward-looking statements should not be read as guarantees of future performance or results, and will not necessarily be accurate indications of whether, or the times at or by which, any particular result will be achieved. No assurance can be given that any events anticipated by the forward-looking information will transpire or occur. Forward-looking information is based on information available at the time and/or management's good-faith belief with respect to future events and is subject to known or unknown risks, uncertainties, assumptions, and other unpredictable factors, many of which are beyond Perimeter's control. Such forward-looking statements reflect Perimeter's current view with respect to future events, but are inherently subject to significant medical, scientific, business, economic, competitive, political, and social uncertainties and contingencies. In making forward-looking statements, Perimeter may make various material assumptions, including but not limited to (i) the accuracy of Perimeter's financial projections; (ii) obtaining positive results from trials; (iii) obtaining necessary regulatory approvals; and (iv) general business, market, and economic conditions. Further risks, uncertainties and assumptions include, but are not limited to, those applicable to Perimeter and described in Perimeter's Management Discussion and Analysis for the year ended December 31, 2025, which is available on Perimeter's SEDAR+ profile at https://www.sedarplus.com, and could cause actual events or results to differ materially from those projected in any forward-looking statements. Perimeter does not intend, nor does Perimeter undertake any obligation, to update or revise any forward-looking information contained in this news release to reflect subsequent information, events, or circumstances or otherwise, except if required by applicable laws.

Contacts

Stephen Kilmer
Investor Relations
Direct: 647-872-4849
Email: [email protected]

Sara Batchelder
Media Relations
Email: [email protected]

Adrian Mendes
Chief Executive Officer
Toll-free: 888-988-7465 (PINK)
Email: [email protected] 

SOURCE Perimeter Medical Imaging AI Inc.